Sarah C Dupont1, Shelly-Ann Fluker2, Kristi M Quairoli3, Cameron Body4, Ike Okosun5, Jennifer Lom2, Lesley S Miller2. 1. School of Medicine and Rollins School of Public Health, Emory University, Atlanta, GA, USA. 2. Division of General Medicine and Geriatrics, Emory University, Atlanta, GA, USA. 3. Department of Pharmacy, Grady Health System, Atlanta, GA, USA. 4. Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA. 5. Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA.
Abstract
OBJECTIVES: We compared outcomes of the hepatitis C virus (HCV) cure cascade (ie, the path a patient follows from diagnosis to cure), including antiviral treatment outcomes, from 2 HCV screening programs. Our objective was to assess whether treatment uptake and HCV cure rates improved in the cohort screened after the release of all-oral HCV direct-acting antiviral therapies. METHODS: We retrospectively compared outcomes of the HCV cure cascade from a cohort of newly diagnosed patients screened during 2012-2014 (period 1) with outcomes from a cohort of newly diagnosed patients screened during 2015-2016 (period 2) at Grady Health System in Atlanta, Georgia. Cure cascade outcomes included HCV antibody (anti-HCV) and RNA testing, linkage to care, antiviral treatment, and sustained virologic response. RESULTS: During period 1, 412 of 5274 (7.8%) persons screened were anti-HCV positive, and 264 (69.3%) of those tested were RNA positive. During period 2, 462 of 7137 (6.5%) persons screened were anti-HCV positive, and 240 (59.3%) of those tested were RNA positive (P = .003). The percentage of newly diagnosed patients who were treated during period 2 (64.0%) was 3 times that of newly diagnosed patients treated during period 1 (21.2%; P < .001). Both cohorts had similarly high levels of linkage to care (95.8% during period 1, 95.4% during period 2) and cure (92.6% during period 1, 95.5% during period 2). CONCLUSIONS: Over time, the prevalence of anti-HCV and HCV RNA positivity declined substantially, and linkage-to-care and cure rates remained high. Treatment uptake increased significantly after the introduction of all-oral direct-acting antiviral therapy. These findings suggest that combining large-scale screening initiatives with treatment programs can speed progress toward HCV elimination.
OBJECTIVES: We compared outcomes of the hepatitis C virus (HCV) cure cascade (ie, the path a patient follows from diagnosis to cure), including antiviral treatment outcomes, from 2 HCV screening programs. Our objective was to assess whether treatment uptake and HCV cure rates improved in the cohort screened after the release of all-oral HCV direct-acting antiviral therapies. METHODS: We retrospectively compared outcomes of the HCV cure cascade from a cohort of newly diagnosed patients screened during 2012-2014 (period 1) with outcomes from a cohort of newly diagnosed patients screened during 2015-2016 (period 2) at Grady Health System in Atlanta, Georgia. Cure cascade outcomes included HCV antibody (anti-HCV) and RNA testing, linkage to care, antiviral treatment, and sustained virologic response. RESULTS: During period 1, 412 of 5274 (7.8%) persons screened were anti-HCV positive, and 264 (69.3%) of those tested were RNA positive. During period 2, 462 of 7137 (6.5%) persons screened were anti-HCV positive, and 240 (59.3%) of those tested were RNA positive (P = .003). The percentage of newly diagnosed patients who were treated during period 2 (64.0%) was 3 times that of newly diagnosed patients treated during period 1 (21.2%; P < .001). Both cohorts had similarly high levels of linkage to care (95.8% during period 1, 95.4% during period 2) and cure (92.6% during period 1, 95.5% during period 2). CONCLUSIONS: Over time, the prevalence of anti-HCV and HCV RNA positivity declined substantially, and linkage-to-care and cure rates remained high. Treatment uptake increased significantly after the introduction of all-oral direct-acting antiviral therapy. These findings suggest that combining large-scale screening initiatives with treatment programs can speed progress toward HCV elimination.
Entities:
Keywords:
baby boomer screening; direct-acting antiviral treatment; hepatitis C; linkage to care
Authors: Lesley S Miller; Francois Rollin; Shelly-Ann Fluker; Kristina L Lundberg; Brandi Park; Kristi Quairoli; Nyiramugisha K Niyibizi; Anne C Spaulding Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Alexander G Geboy; Sandeep Mahajan; Allison P Daly; Candice F Sewell; Ike C Fleming; Hyun A Cha; Idene E Perez; Carmella A Cole; Adebisi A Ayodele; Dawn A Fishbein Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Stefan Zeuzem; Reem Ghalib; K Rajender Reddy; Paul J Pockros; Ziv Ben Ari; Yue Zhao; Deborah D Brown; Shuyan Wan; Mark J DiNubile; Bach-Yen Nguyen; Michael N Robertson; Janice Wahl; Eliav Barr; Joan R Butterton Journal: Ann Intern Med Date: 2015-07-07 Impact factor: 51.598